News & Press Releases

Mintz advised the placement agent in connection with SCYNEXIS’ up to $92.2 million private placement. The private placement included upfront gross proceeds of approximately $40.0 million in common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants, and up to an additional $52.2 million in gross proceeds if the common warrants are exercised for cash, subject to stockholder approval to increase the number of authorized shares of common stock.

David Adams was quoted in a CFO Dive article analyzing the challenges facing efforts to pass comprehensive federal AI legislation, and what the ongoing political gridlock and competing state-level approaches mean for businesses.

Of Counsel Michelle Capezza was quoted in a Business Insider article examining the push to expand private credit and other alternative investments into 401(k) retirement plans. The article discusses these developments in light of new regulations proposed by the Department of Labor, as well as ongoing questions about liquidity, valuation, and market volatility within the private credit space.

Mintz has again been recognized as one of the most active and high-performing law firms for patent prosecution in Patexia’s LexDana 2026 Patent Prosecution Intelligence Report, reflecting the depth and breadth of the firm’s patent prosecution practice across biotechnology, high‑tech, and other innovation‑driven technologies.

Michael Arnold, Chair of Mintz’s Employment Practice, was featured on a recent episode of the Corner Office with Elise Powers podcast, where he spoke about leadership, wellbeing, and sustaining a long-term career in Big Law.

Mintz represented Synnovation Therapeutics LLC, a clinical-stage biotechnology company with a diverse pipeline of novel small-molecule targeted therapies in oncology and immunology, in connection with its definitive agreement with Novartis to acquire Synnovation’s wholly-owned subsidiary, Pikavation Therapeutics Inc., and its portfolio of pan mutant selective PI3Kα inhibitor programs, including its lead clinical asset SNV4818.